Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
Savara announced an encore presentation of Phase 3 IMPALA-2 trial results for Molgramostim inhalation solution in patients with autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the upcoming British Thoracic Society Winter Meeting 2024. The presentation titled 'Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life in Patients with aPAP' will be delivered by Dr. Cormac McCarthy on November 29, 2024, in London. The presentation will showcase how the treatment improves pulmonary gas exchange and respiratory health-related quality of life in aPAP patients.
Savara ha annunciato una presentazione di riepilogo dei risultati del trial Phase 3 IMPALA-2 per la soluzione inalatoria di Molgramostim nei pazienti con Proteinosi Alveolare Polmonare autoimmune (aPAP) durante il prossimo British Thoracic Society Winter Meeting 2024. La presentazione, intitolata 'Il Molgramostim inalato migliora lo scambio gassoso polmonare e la qualità della vita legata alla salute respiratoria nei pazienti con aPAP', sarà tenuta dal Dr. Cormac McCarthy il 29 novembre 2024 a Londra. La presentazione metterà in evidenza come il trattamento migliori lo scambio gassoso polmonare e la qualità della vita respiratoria nei pazienti con aPAP.
Savara anunció una presentación en repetición de los resultados del ensayo Phase 3 IMPALA-2 para la solución de inhalación de Molgramostim en pacientes con Proteinosis Alveolar Pulmonar autoinmune (aPAP) en la próxima reunión de invierno de la British Thoracic Society 2024. La presentación, titulada 'Molgramostim inhalado mejora el intercambio de gases pulmonares y la calidad de vida relacionada con la salud respiratoria en pacientes con aPAP', será realizada por el Dr. Cormac McCarthy el 29 de noviembre de 2024 en Londres. La presentación mostrará cómo el tratamiento mejora el intercambio de gases pulmonares y la calidad de vida relacionada con la salud respiratoria en pacientes con aPAP.
사바라는 자가면역 폐포 단백증(aPAP) 환자에 대한 몰그램로스팀 흡입 용액의 3상 IMPALA-2 시험 결과에 대한 앙코르 발표를 예정된 2024년 영국 흉부 학회 겨울 회의에서 발표한다고 발표했습니다. '흡입된 몰그램로스팀이 aPAP 환자의 폐 가스 교환 및 호흡기 건강 관련 삶의 질을 개선한다'는 제목의 발표는 2024년 11월 29일 런던에서 Cormac McCarthy 박사에 의해 진행될 것입니다. 이 발표는 해당 치료가 aPAP 환자의 폐 가스 교환 및 호흡기 건강 관련 삶의 질을 어떻게 개선하는지를 보여줄 것입니다.
Savara a annoncé une présentation supplémentaire des résultats de l'essai Phase 3 IMPALA-2 pour la solution inhalatoire de Molgramostim chez les patients atteints de proténose alvéolaire pulmonaire auto-immune (aPAP) lors de la prochaine réunion d'hiver de la British Thoracic Society 2024. La présentation, intitulée 'Le Molgramostim inhalé améliore l'échange gazeux pulmonaire et la qualité de vie liée à la santé respiratoire chez les patients atteints d'aPAP', sera présentée par le Dr Cormac McCarthy le 29 novembre 2024 à Londres. Cette présentation mettra en lumière comment le traitement améliore l'échange gazeux pulmonaire et la qualité de vie liée à la santé respiratoire chez les patients atteints d'aPAP.
Savara kündigte eine Encore-Präsentation der Ergebnisse der Phase 3 IMPALA-2 Studie zur Inhalationslösung von Molgramostim bei Patienten mit autoimmuner alveolärer Proteinosis (aPAP) an, die beim kommenden British Thoracic Society Winter Meeting 2024 stattfinden wird. Die Präsentation mit dem Titel 'Inhalierter Molgramostim verbessert den pulmonalen Gasaustausch und die gesundheitsbezogene Lebensqualität bei Patienten mit aPAP' wird von Dr. Cormac McCarthy am 29. November 2024 in London gehalten. In der Präsentation wird gezeigt, wie die Behandlung den pulmonalen Gasaustausch und die gesundheitsbezogene Lebensqualität bei aPAP-Patienten verbessert.
- None.
- None.
BTS Platform Presentation Details
Title: “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-2”
Platform Presentation Spoken Session: S107-S111 “The Famous Five” — Emerging clinical trial data
Date and Time: November 29, 2024, 8:30am – 9:50am GMT
Location: QEII Centre,
Speaker: Cormac McCarthy, M.D., Ph.D., FRCPI, Associate Professor of Medicine at the University College Dublin (UCD) and Consultant Respiratory Physician at St. Vincent’s University Hospital in
Following the session, the presentation slides will be available on the Articles & Publications page of the Company’s corporate website.
About aPAP
Autoimmune PAP (aPAP) is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli (or air sacs) of the lungs. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in aPAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long-term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, X:@SavaraPharma and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241122038208/en/
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com
Source: Savara Inc.
FAQ
When will Savara (SVRA) present the IMPALA-2 trial results at the British Thoracic Society Winter Meeting?
What are the key findings of Savara's (SVRA) Phase 3 IMPALA-2 trial with Molgramostim?
Who will present Savara's (SVRA) IMPALA-2 trial results at the BTS Winter Meeting 2024?
